{"id":251100,"date":"2022-02-28T00:00:00","date_gmt":"2022-02-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcg0148-biopharma-huntingtons-disease-epidemiology-middle-east\/"},"modified":"2026-04-28T11:21:01","modified_gmt":"2026-04-28T11:21:01","slug":"epidcg0148-biopharma-huntingtons-disease-epidemiology-middle-east-africa","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0148-biopharma-huntingtons-disease-epidemiology-middle-east-africa\/","title":{"rendered":"Huntington&#8217;s Disease &#8211; Epidemiology &#8211; Middle East &#038; Africa"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of Huntington&#8217;s disease (<abbr title=\"Huntington\u2019s disease\">HD<\/abbr>) comprises epidemiological estimates of key patient populations in the Middle East &#038; Africa (Egypt, Nigeria, Saudi Arabia, and South Africa). We report the prevalence of <abbr title=\"Huntington\u2019s disease\">HD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"Huntington\u2019s disease\">HD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"Huntington\u2019s disease\">HD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In addition to the diagnosed prevalent cases, Clarivate Epidemiology forecasts data for the following <abbr title=\"Huntington\u2019s disease\">HD <\/abbr>populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed manifest incident cases.<\/li>\n<li>Diagnosed manifest prevalent cases.<\/li>\n<li>Diagnosed prevalence at risk.<\/li>\n<li>Diagnosed manifest stage I prevalent cases.<\/li>\n<li>Diagnosed manifest stage II prevalent cases.<\/li>\n<li>Diagnosed manifest stage III prevalent cases.<\/li>\n<li>Diagnosed manifest stage IV prevalent cases.<\/li>\n<li>Diagnosed manifest stage V prevalent cases.<\/li>\n<li>Diagnosed prevalence high risk.<\/li>\n<li>Diagnosed prevalence low risk.<\/li>\n<li>Diagnosed premanifest prevalent cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251100","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-huntingtons-disease","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-geography-middle-east-africa","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251100\/revisions"}],"predecessor-version":[{"id":576268,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251100\/revisions\/576268"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}